Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517421 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
A Phase 3 study, sponsored by Immunovant Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
NCT05517421 is a Phase 3 study that has completed, run by Immunovant Sciences. The registered enrollment target is 114 participants.
The verdict
NCT05517421, a Phase 3 study, has completed, sponsored by Immunovant Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
Study Summary
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Interventions
- DRUG Placebo
- DRUG Batoclimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2022-11-23 |
| Est. Completion | 2025-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05517421
The ClinicalTrials.gov registry entry for NCT05517421 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05517421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05517421 about?
NCT05517421 is a clinical study titled "Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease". To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
What is the current status of trial NCT05517421?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2022-11-23. Estimated completion is 2025-11-18.
What interventions are being tested in trial NCT05517421?
The interventions under investigation include: Placebo (DRUG), Batoclimab (DRUG).
Who is sponsoring clinical trial NCT05517421?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.